

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
08 August 2024 (08.08.2024)



(10) International Publication Number
WO 2024/163737 A1

(51) International Patent Classification:

C12N 9/24 (2006.01) A61P 25/28 (2006.01)
A61K 48/00 (2006.01) C12N 15/86 (2006.01)

(21) International Application Number:

PCT/US2024/014000

(22) International Filing Date:

01 February 2024 (01.02.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/US2023/061837

02 February 2023 (02.02.2023) US

(71) Applicant: VOYAGER THERAPEUTICS, INC.

[US/US]; 75 Hayden Ave, Lexington, Massachusetts 02421 (US).


(72) Inventors: **CHUNG, Hiu Yan**; 75 Hayden Ave, Lexington, Massachusetts 02421 (US). **KNOLL, Elisabeth**; 75 Hayden Ave, Lexington, Massachusetts 02421 (US). **CARTER, Todd**; 75 Hayden Ave, Lexington, Massachusetts 02421 (US).

(74) Agent: **JACOBSTEIN, Jeffrey M.**; Finnegan, Henderson, Farabow, Garrett & Dunner, LLP, 901 New York Avenue, NW, Washington, District of Columbia 20001-4413 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,

(54) Title: COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS RELATED TO GLUCOSYL CERAMIDASE BETA 1 DEFICIENCY

FIG. 3



(57) Abstract: The disclosure relates to compositions and methods for altering, *e.g.*, enhancing, the expression of GCase proteins, whether *in vitro* and/or *in vivo*. Such compositions include delivery of an adeno-associated viral (AAV) particle. The compositions and methods of the present disclosure are useful in the treatment of subjects diagnosed with, or suspected of having Parkinson's Disease (PD), Gaucher Disease (GD), Dementia with Lewy Bodies (DLB), or related condition resulting from a deficiency in the quantity and/or function of GBA1 gene product or associated with decreased expression or protein levels of GCase protein.

[Continued on next page]

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

- (84) Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*